The litigation landscape around compounded GLP-1 medications has intensified dramatically in 2026. Novo Nordisk and Eli Lilly are pursuing a multi-front legal strategy targeting compounding pharmacies, telehealth platforms, and peptide suppliers. Here's the current state of play.

The Legal Strategy

Manufacturer litigation operates on three tracks simultaneously: trademark infringement suits against companies using brand names (Ozempic, Wegovy, Zepbound) or similar branding in marketing, patent infringement claims against compounders producing molecules covered by active patents, and civil suits alleging unfair competition and consumer deception. Additionally, both companies have been sending cease-and-desist letters to compounders at an accelerating pace.

Key Active Cases

While the exact number of active suits fluctuates, legal tracking suggests well over 100 active cease-and-desist letters and dozens of formal litigation filings as of July 2026. The manufacturers are pursuing cases across multiple federal districts, though the Northern District of Texas has been a particularly active venue given its jurisdiction over key regulatory challenges.

Patient Impact
Manufacturer lawsuits can cause providers to abruptly cease operations. If your compounding pharmacy or telehealth platform suddenly closes, you may experience a supply interruption. Maintain records of your prescription, current dose, and provider contact information. Consider having a backup provider relationship established before you need it.

What This Means for Patients

Patients are not the targets of manufacturer litigation. Novo Nordisk and Eli Lilly are suing companies, not individuals. You will not face legal consequences for using compounded GLP-1 medications prescribed by a licensed provider and prepared by a licensed pharmacy.

However, manufacturer litigation can indirectly affect you by reducing the number of available providers, increasing costs as surviving providers pass along legal compliance expenses, and creating supply uncertainty if your specific provider is targeted.

The best protection is using verified, properly licensed 503A pharmacies with documented compliance practices. These providers are better positioned to withstand legal pressure because their operations are legitimately structured within the existing regulatory framework.

Verified Providers with Legal Staying Power

We monitor our listed providers for regulatory and legal stability.

See Stable Providers →